Denali Therapeutics (DNLI) Invested Capital (2017 - 2025)
Historic Invested Capital for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $931.8 million.
- Denali Therapeutics' Invested Capital fell 2962.97% to $931.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $931.8 million, marking a year-over-year decrease of 2962.97%. This contributed to the annual value of $1.2 billion for FY2024, which is 2018.24% up from last year.
- Latest data reveals that Denali Therapeutics reported Invested Capital of $931.8 million as of Q3 2025, which was down 2962.97% from $1.0 billion recorded in Q2 2025.
- Denali Therapeutics' 5-year Invested Capital high stood at $1.5 billion for Q1 2024, and its period low was $812.7 million during Q3 2022.
- Over the past 5 years, Denali Therapeutics' median Invested Capital value was $1.0 billion (recorded in 2022), while the average stood at $1.1 billion.
- Per our database at Business Quant, Denali Therapeutics' Invested Capital skyrocketed by 11361.52% in 2021 and then tumbled by 2962.97% in 2025.
- Over the past 5 years, Denali Therapeutics' Invested Capital (Quarter) stood at $962.3 million in 2021, then increased by 8.78% to $1.0 billion in 2022, then decreased by 1.52% to $1.0 billion in 2023, then increased by 20.18% to $1.2 billion in 2024, then decreased by 24.79% to $931.8 million in 2025.
- Its Invested Capital was $931.8 million in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.1 billion in Q1 2025.